The prognostic value of baseline clinical parameters in predicting the survival prolonging effect of radium-223-dichloride (223Ra)-therapy in metastatic castration resistant prostate cancer (mCRPC) patients is still an open issue. The aim of this study was investigating the impact of baseline quality of life (QoL) on overall survival (OS) in mCRPC patients treated with 223Ra. The present study also evaluated the trend of patient-reported QoL during both 223Ra-treatment and post-therapy follow-up period.
Frantellizzi, V., De Feo, M.s., Di Rocco, A., Pontico, M., Pani, A., Farcomeni, A., et al. (2020). Baseline quality of life predicts overall survival in patients with mCRPC treated with 223Ra-dichloride. HELLENIC JOURNAL OF NUCLEAR MEDICINE, 23(1), 12-20 [10.1967/s002449912001].
Baseline quality of life predicts overall survival in patients with mCRPC treated with 223Ra-dichloride
Farcomeni, Alessio;
2020-01-01
Abstract
The prognostic value of baseline clinical parameters in predicting the survival prolonging effect of radium-223-dichloride (223Ra)-therapy in metastatic castration resistant prostate cancer (mCRPC) patients is still an open issue. The aim of this study was investigating the impact of baseline quality of life (QoL) on overall survival (OS) in mCRPC patients treated with 223Ra. The present study also evaluated the trend of patient-reported QoL during both 223Ra-treatment and post-therapy follow-up period.| File | Dimensione | Formato | |
|---|---|---|---|
|
qol223.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
1.73 MB
Formato
Adobe PDF
|
1.73 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
